BTIG Maintains Buy on GeneDx Hldgs, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $19 to $35.
June 26, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Mark Massaro has maintained a Buy rating on GeneDx Holdings and raised the price target from $19 to $35, indicating strong confidence in the company's future performance.
The increase in the price target from $19 to $35 by a reputable analyst suggests a positive outlook for GeneDx Holdings. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100